Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells.

[1]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[2]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[3]  H. Lähdesmäki,et al.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex , 2015, Nature Communications.

[4]  Bing Li,et al.  Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia , 2015, Experimental Hematology & Oncology.

[5]  E. Vellenga,et al.  Erythroid progenitors from patients with low-risk myelodysplastic syndromes are dependent on the surrounding micro environment for their survival. , 2015, Experimental hematology.

[6]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[7]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[8]  O. Abdel-Wahab,et al.  Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.

[9]  B. Ebert,et al.  MDS is a stem cell disorder after all. , 2014, Cancer cell.

[10]  Zhaomin Li,et al.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. , 2014, Blood.

[11]  C. Mason,et al.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.

[12]  H. Aburatani,et al.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. , 2013, The Journal of clinical investigation.

[13]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[14]  E. Vellenga,et al.  Sinusoidal endothelial cells are damaged and display enhanced autophagy in myelodysplastic syndromes , 2013, British journal of haematology.

[15]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[17]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[18]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Li Ding,et al.  Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.

[20]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[21]  Michael Heuser,et al.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.

[22]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[23]  E. Vellenga,et al.  Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria , 2009, Leukemia.

[24]  H. Deeg,et al.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. , 2007, Experimental hematology.

[25]  E. Vellenga,et al.  STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. , 2007, Blood.

[26]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[27]  P. Fernandez,et al.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.

[28]  U. Thorsteinsdóttir,et al.  NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice , 2001, The EMBO journal.

[29]  N. Schmitz,et al.  ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome , 2013, Leukemia.

[30]  H. Deeg,et al.  Apoptosis and anti-apoptotic mechanisms in the progression of MDS , 2007 .